Beckman Coulter has received approval for the UniCel® DxH 800 Cellular Analysis System that promises faster and better results from more samples that arrive at the hospital’s clinical lab.
From the press release:
Capturing 29 individual measurements per cell analyzed, the system provides improved sensitivity and specificity, which means more reliable assessment of abnormal cell populations. Laboratories equipped with the system will be able to respond more quickly and accurately to physician demands, improving patient health and reducing the cost of care.
The system’s all new physical design—demonstrated by more than 40 new and pending patents—minimizes moving parts, increasing instrument reliability and technologist efficiency. The modular and scalable design makes the DxH 800 the ultimate solution for a variety of market segments. Multiple systems can be connected easily into a work cell to meet the volume needs of a broad range of labs, from mid- to very-high volumes. A unique magnetic Specimen Transport Module (STM) transports cassettes between connected instruments with no track required.
Future platform enhancements include an automated Slide Maker/Stainer, featuring the same patented STM technology for transporting samples. A single SMS unit will support multiple DxH 800 systems, automatically balancing the workload for connected systems and making slides based on user-defined Decision Rules, without operator intervention.
Another significant future enhancement will be the incorporation of flow cytometry technology which will further extend the DxH 800 systems’ ability to yield an unparalleled breadth of information. This new capability will decrease the number of manual reviews required today—greatly enhancing the efficiency of the laboratory, while extending the cellular analysis menu of tomorrow. Future applications may include monitoring provisions for Sepsis, Cancer, HIV, Diabetes and other high value disease states.
Press release: Beckman Coulter Announces FDA Clearance of UniCel® DxH 800 …